Panagiotis Zagaliotis, PhD
Panagiotis graduated from the Pharmacy School at the Aristotle University of Thessaloniki, Greece, and subsequently received his Masters in Medicinal Chemistry at the same university, focusing on the synthesis, molecular target identification and structure elucidation of aromatic compounds with potential dual antimicrobial and anti-inflammatory activity. During his Masters he mostly worked on the synthesis of 1,3,4-thiadiazole derivatives, with extensive focus on Nuclear Magnetic Resonance (NMR) for structure elucidation, in vitro antimicrobial susceptibility testing, and in vivo applications in murine models, among which was the investigation of the anti-inflammatory activity with the use of the carrageenan-induced paw edema. As part of his Masters work, he refined his skills in Thin Layer Chromatography (TLC), infrared (IR) spectroscopy, recrystallization and purification techniques, and molecular docking for identification of potential drug targets of the compounds.
Following the completion of his MSc, he was accepted in the PhD program of the Department of Pharmacology at the Aristotle University, in collaboration with the Division of Infectious Diseases at Weill Cornell Medicine, under the co-mentorship of Drs. Ioannis Vizirianakis and Thomas J. Walsh. During his PhD, he worked on bacteriophage therapy of Gram-negative bacterial infections, and more specifically carbapenem-resistant Klebsiella pneumoniae (KPC). His PhD work focused on the isolation and characterization of bacteriophages selective against KPC, and the investigation of their efficacy in vivo in murine models of KPC gastrointestinal colonization and infection. As the pandemic of COVID-19 occurred during the second year of his PhD studies, he also worked on the identification of potential novel antimicrobials against COVID-19, with potential dual activity against the cytopathic pathway of the virus, as well as against the inflammatory cascade of SARS-CoV-2 infection. In February 2023, he joined the Ndhlovu laboratory to work on the use of bacteriophages as a potential strategy to combat HIV-related dysbiosis in the gastrointestinal tract.
Research Interest: bacteriophage therapy, bacterial infections, HIV-related gut dysbiosis, wound infection mucormycosis, COVID-19 drug screening, in vivo murine models, physiologically-based pharmacokinetic (PBPK) modelling, organic synthesis, NMR spectroscopy
Henry Shcueler 41&9 Foundation Fellow for research of wound infection invasive mucormycosis (2023)
Fun Fact: Panagiotis is a teacher of Byzantine music, with students ranging from the ages of 9-65 years old. He is also a certified instructor of martial arts, and more specifically Wing Chun Kung Fu, which he has been practicing for 16 years.
Hometown: Serres, Greece
PharmD, Aristotle University of Thessaloniki, Greece
MSc, Medicinal Chemistry, Aristotle University of Thessaloniki
PhD (ongoing), Pharmacology – Infectious Diseases, Aristotle University of Thessaloniki – Weill Cornell Medicine
Haroun M, Petrou A, Tratrat C, Kolokotroni A, Fesatidou M, Zagaliotis P, Gavalas A, Venugopala KN, Sreeharsha N, Nair AB, Elsewedy HS, Geronikaki A. Discovery of 5-Methylthiazole-Thiazolidinone Conjugates as Potential AntiInflammatory Agents: Molecular Target Identification and In Silico Studies. Molecules. 2022; 27(23):8137. https://doi.org/10.3390/molecules27238137
Zagaliotis P, Michalik-Provasek J, Gill J, Walsh T. Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. PAI. 2022 Oct. 17;7(2):1-45. doi: 10.20411/pai.v7i2.516
Chen TK, Batra JS, Michalik DE, Casillas J, Patel R, Ruiz M, Hara H, Patel B, Kadapakkam M, Ch'Ng J, Small CB, Zagaliotis P, Ragsdale CE, Leal LO, Roilides E, Walsh TJ. Recombinant Human Granulocyte-Macrophage ColonyStimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases, Open Forum Infect Dis, 2022;, ofac535, doi: 10.1093/ofid/ofac535
Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ. Developing New Treatments for COVID-19 through Dual-Action Antiviral/AntiInflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. Int J Mol Sci. 2022 Jul 20;23(14):8006. doi: 10.3390/ijms23148006. 3
Petrou A, Zagaliotis P, Theodoroula NF, Mystridis GA, Vizirianakis IS, Walsh TJ, Geronikaki A. Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2. Molecules. 2022 Mar 28;27(7):2180. doi: 10.3390/molecules27072180.
Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res. 2021 Jun 28;10:507. doi: 10.12688/f1000research.28327.2. 7. Michalik-Provasek J, Lessor L, Mavridou E, Zagaliotis P, Walsh T, Gill J. Developing and characterizing bacteriophage for therapeutic use against carbapenem‐resistant Enterobacteriaceae in a multiple drug resistant Klebsiella pneumoniae model. The FASEB Journal 34 (S1), 1-1. Doi: 10.1096/fasebj.2020.34.s1.00500.
Fesatidou M, Zagaliotis P, Camoutsis C, Petrou A, Eleftheriou P, Tratrat C, Haroun M, Geronikaki A, Ciric A, Sokovic M. 5-Adamantan thiadiazole-based thiazolidinones as antimicrobial agents. Design, synthesis, molecular docking and evaluation. Bioorg Med Chem. 2018 Sep 1;26(16):4664-4676. doi: 10.1016/j.bmc.2018.08.004.